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 Stroke and heart-related diseases are one of the leading causes of deaths in United 
States. There are many factors that may cause stroke, and left atrial appendage 
coagulation is one of them. Left atrial appendage coagulation is a coagulation of blood 
inside the left atrial appendage caused by atrial fibrillation, not rhythmical contraction of 
your heart muscle. For left atrial appendage, not like other heart defects, anti-coagulant 
currently is only solution to solve this problem. There isn’t any implant device solution 
specific for left atrial appendage occlusion. However, there are some devices that are 
currently going through FDA approval process. These are Watchman and Lariat. 
According to interviews performed with cardiac specialists throughout Atlanta, they are 
emphasizing three major factors. They are stability, customizability, and full occlusion. 
Limitations of Watchman and Lariat are customizability and full occlusion. To satisfy all 
three factors and to improve from Lariat and Watchman, Flow Medical has come up with 












Statistics & Definition 
 There are four million people suffering from atrial fibrillation. This number is 
projected to reach 12 to 16 million by the time of 2050 [1]. If these statistics are 
considered economically, the medical expense is projected to reach market value of 22.8 
billion. 
 Among all the diseased conditions related to irregularly timed contraction, atrial 
fibrillation is the most common one. Frequently, atrial fibrillation gives an excessive load 
on the left atrial appendage, and it leads to an enlargement of the left atrial appendage. 
 By definition, atrial fibrillation patients have irregular contractions of their heart 
muscle. This is caused due to irregularly synchronized signals on different nodes of the 
heart. This irregular contraction of the heart, atrial fibrillation, may cause some serious 
problems. Left atrial appendage coagulation is one of them. 
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Figure 1. Atrial Fibrillation. By definition, atrial fibrillation patients have irregular 
contractions of their heart muscle. This is caused due to irregularly synchronized signals 
on different nodes of the heart. 
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CHAPTER 2 
LEFT ATRIAL APPENDAGE 
 
STRUCTURE 
 The left atrial appendage is located on left side of your left atrium. It is a finger 
like projection and comes in various shapes, and its length is about 2-4 cm pointing 
toward the apex. 
 
Figure 2. The left atrial appendage is located on left side of your left atrium. It is a finger 
like projection and comes in various shapes, and its length is about 2-4 cm pointing 




COAGULATION & STROKE 
  
For patients with left atrial appendage coagulation, the blood flow into the left 
atrial appendage, and it does not come back out due to lack of contractions. After some 
amount of time, the arrested blood will get clogged inside the left atrial appendage. The 
coagulation of blood is formed. This small coagulation, in the size of left atrial appendage, 
will escape out of the left atrial appendage. It may travel through different vessels.  
 
 As this small piece of coagulation is traveling through the system, it may get 
stuck in different vascular systems such as heart, brain, and vessels. It may be developed 
to a serious stroke by blocking the blood flow on whatever region that it settles on. If 
atrial fibrillation is left untreated, risk of stroke of those individuals increases as they age. 
According to statistics, 15% of strokes are caused by atrial fibrillation [2]. For patients 












 In the medical industry today, the only used to treat atrial fibrillation is anti-
coagulant. However, the average age of atrial fibrillation is 75 years old [4]. This age 
factor makes anti-coagulants a very dangerous solution. A simple paper cut may be 
turned into a catastrophic emergency if the patient is on coagulants because the blood 
flow will not be able to be stopped. If patients fall from stairs or any kind of internal 
bleeding, this may be lead to serious event as well. 
 Warfarin, an active ingredient in rodenticide agents, is the current standard 
treatment to decrease the risk of stroke in atrial fibrillation patients. The mechanism of 
this anticoagulant is working by inhibiting various clotting factors in the blood stream to 
prevent formation of clots. For entire atrial fibrillation population, only 70% of those 
population are considered ideal candidates for Warfarin [5]. This already leaves out 30% 
of atrial patients in potential risk of stroke. 
 On top of this, due to potential complications from a blood thinning medicine and 
multiple risk factors, the percentage has been cut down to as few as 25% of atrial 
fibrillation patients. 
 
However, there are serious side effects with using anti-coagulant. Anti-coagulants 
fail to approach the heart of the matter. For this reason, there are two devices out there, 
which are approaching the heart of the problem, rather than taking alternative route to 
inhibit the matter. These two devices are Watchman and Lariat, and these devices are 
under FDA approval process to become legitimate left atrial appendage occlusion devices. 
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WATCHMAN (INTRACARDIAC DEVICE) 
 The watchman is an intracardiac device that been supported by a FDA panel and 
looking to acquire FDA approval. The device is installed inside heart using catherization 
and transeptal puncture method. The material of device is made of polyethylene 
terephthalate (PET) and nitinol, functioning memory-shaping and occluding. After 
implantation, patients must take the anti-coagulant for 45 days until scar tissue forms 
over it increasing the occlusal and stability properties. However, even this device cannot 
fully occlude the region due to not enough regenerative abilities. 
 
Figure 3. Watchman Intracardiac Device. The watchman is an intracardiac device made 







 Lariat is actually approved by FDA for soft tissue occlusion, but not specifically 
for left atrial appendage. The device made of Teflon and polyester is guided towards the 
left atrial appendage periodically by a magnet attracting from inside the hart this device 
actually does provide highly accurate closure rate. The biggest problem with this device 
is the complexity of procedure in implanting this device. The procedure requires the 
electro-physician to spend a fair amount of time and effort, and it shows a steep learning 
curve for surgeons to learn this procedure. 
 
 
Figure 4. Lariat. The device made of Teflon and polyester is guided towards the left atrial 
appendage periodically by a magnet attracting from inside the hart this device actually 




BALLOON OCCLUSION DEVICE 
As it has discussed in chapter 3, there is still room for improvement in this 
procedure. The only current solution, anti-coagulant, is just an alternative solution to fix 
the problem since there isn’t any solution specific to the left atrial appendage that is FDA 
approved yet. As discussed on chapter 3, there are two devices that are going through the 
FDA approval, but they still do have problems in them. Flow Medical, founded by Arnab 
Chakraborty and Christine Hang, is currently working on design iteration for developing 
left atrial appendage occlusion device. 
 
 
Figure 5. Flow Medical Left Atrial Occlusion Balloon. This balloon is consisted of two 
major compartments that will be filled up separately by Hydrogel through hydrogel 
insertion needle. The material is biocompatible medical silicone, and its surface will be 
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